P

Inventor

COCHRAN Michael Caramian

US33 patents

Patents

33 patents
US10550188B2Feb 4, 2020

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC80 citations98
US11179472B2Nov 23, 2021

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

AVIDITY BIOSCIENCES INC35 citations97
US10994020B2May 4, 2021

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

AVIDITY BIOSCIENCES INC32 citations97
US10881743B2Jan 5, 2021

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC55 citations97
US12064483B2Aug 20, 2024

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

AVIDITY BIOSCIENCES INC19 citations94
US11400163B2Aug 2, 2022

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

AVIDITY BIOSCIENCES INC26 citations94
US11311627B1Apr 26, 2022

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

AVIDITY BIOSCIENCES INC28 citations94
US11110180B2Sep 7, 2021

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC19 citations93
US10787519B2Sep 29, 2020

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC19 citations93
US10487149B2Nov 26, 2019

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC21 citations93
US11576980B2Feb 14, 2023

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC6 citations85
US11446387B2Sep 20, 2022

Compositions and methods of treating muscle dystrophy

AVIDITY BIOSCIENCES INC8 citations85
US11253607B2Feb 22, 2022

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC7 citations85
US11246941B2Feb 15, 2022

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC7 citations85
US11554176B2Jan 17, 2023

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC2 citations84
US11497814B2Nov 15, 2022

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC3 citations84
US10800848B2Oct 13, 2020

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC7 citations83
US12427202B2Sep 30, 2025

Compositions and methods of treating muscle dystrophy

AVIDITY BIOSCIENCES INC1 citations74
US12006499B2Jun 11, 2024

Una amidites and uses thereof

AVIDITY BIOSCIENCES INC2 citations73
US11583591B2Feb 21, 2023

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC2 citations73
US11872287B2Jan 16, 2024

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC1 citations72
US11707532B2Jul 25, 2023

Compositions and methods of treating muscle dystrophy

AVIDITY BIOSCIENCES INC3 citations72
US11364302B1Jun 21, 2022

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC2 citations71
US12497615B2Dec 16, 2025

Nucleic acid compositions and methods of multi-exon skipping

AVIDITY BIOSCIENCES INC0 citations62
US12365704B2Jul 22, 2025

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC0 citations62
US12351637B2Jul 8, 2025

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC0 citations62
US12234290B2Feb 25, 2025

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC0 citations62
US11712478B2Aug 1, 2023

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC0 citations62
US11578090B2Feb 14, 2023

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC1 citations62
US12364769B2Jul 22, 2025

Nucleic acid-polypeptide compositions and uses thereof

AVIDITY BIOSCIENCES INC0 citations61
US12263224B2Apr 1, 2025

Compositions and methods of treating muscle atrophy and myotonic dystrophy

AVIDITY BIOSCIENCES INC0 citations61
US12359202B2Jul 15, 2025

Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

AVIDITY BIOSCIENCES INC1 citations58
US12071621B2Aug 27, 2024

Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

AVIDITY BIOSCIENCES INC1 citations56